Susquehanna International Group
CCCC icon

Susquehanna International Group’s C4 Therapeutics CCCC Stock Holding History

Susquehanna International Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.09M Buy
1,732,210
+445,370
+35% +$1.52M ﹤0.01% 3734
2026
Q1 		$3.38M Sell
1,286,840
-488,943
-28% -$1.15M ﹤0.01% 5024
2025
Q4 		$3.39M Buy
1,775,783
+1,260,346
+245% +$2.99M ﹤0.01% 4656
2025
Q3 		$1.14M Buy
515,437
+374,381
+265% +$899K ﹤0.01% 7027
2025
Q2 		$202K Buy
141,056
+67,274
+91% +$97.8K ﹤0.01% 11196
2025
Q1 		$118K Buy
73,782
+29,559
+67% +$88.2K ﹤0.01% 11423
2024
Q4 		$159K Sell
44,223
-5,884
-12% -$29.3K ﹤0.01% 10968
2024
Q3 		$286K Buy
50,107
+6,077
+14% +$36.6K ﹤0.01% 9700
2024
Q2 		$203K Sell
44,030
-443,621
-91% -$2.65M ﹤0.01% 10326
2024
Q1 		$3.98M Sell
487,651
-514,862
-51% -$3.99M ﹤0.01% 4022
2023
Q4 		$5.66M Buy
1,002,513
+840,650
+519% +$1.92M ﹤0.01% 3499
2023
Q3 		$301K Sell
161,863
-63,329
-28% -$193K ﹤0.01% 9341
2023
Q2 		$619K Sell
225,192
-42,875
-16% -$138K ﹤0.01% 7808
2023
Q1 		$842K Buy
268,067
+252,406
+1,612% +$1.49M ﹤0.01% 7273
2022
Q4 		$92.4K Sell
15,661
-27,209
-63% -$226K ﹤0.01% 11025
2022
Q3 		$376K Buy
+42,870
New +$445K ﹤0.01% 9207
2022
Q2 		– Sell
-37,520
Closed -$330K – 12960
2022
Q1 		$910K Buy
37,520
+2,691
+8% +$65.3K ﹤0.01% 7367
2021
Q4 		$1.12M Sell
34,829
-8,586
-20% -$340K ﹤0.01% 6994
2021
Q3 		$1.94M Buy
43,415
+19,888
+85% +$852K ﹤0.01% 5905
2021
Q2 		$890K Buy
23,527
+17,255
+275% +$618K ﹤0.01% 8082
2021
Q1 		$232K Buy
+6,272
New +$250K ﹤0.01% 11127

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Susquehanna International Group's CCCC Position: Q2 2026 in Review

Susquehanna International Group increased its C4 Therapeutics (CCCC) stake by 35% in Q2 2026, buying an estimated $1.52M and bringing the position to 1,732,210 shares worth $8.09M. The position accounts for ﹤0.01% of the portfolio, ranked #3734.

Susquehanna International Group first reported a position in CCCC in Q1 2021 and has held it in 21 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Susquehanna International Group held 1,732,210 shares of C4 Therapeutics worth $8.09M as of Q2 2026.
  • Susquehanna International Group bought 445,370 C4 Therapeutics shares in Q2 2026, an estimated $1.52M.
  • C4 Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #3734 holding.
  • Susquehanna International Group first reported a position in C4 Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.